1. Remdesivir was assessed for cardiac safety in COVID-19 patients.
2. Analysis included 4566 adults with data from 7 trials.
3. 6.6% of patients experienced cardiac adverse events.
4. No significant differences found between treatment groups.
5. Moderate certainty for overall CAEs, low for arrhythmias and heart failure.
6. Further research is needed on long-term outcomes and vaccinated populations.

Source: BMJ Open